OVID

Healthcare Biotechnology

Ovid Therapeutics Inc.

$2.35

-0.07 -2.73% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 9:37 AM ET	2.35

Key Stats

Market Cap

459.73M

Avg Volume

1.63M

EPS

-$0.22

52W High

$3.11

52W Low

$1.18

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-6.08

P/B Ratio

2.07

P/S Ratio

290.42

EV/EBITDA

-6.21

EV/Revenue

227.61

Margins

Gross Margin 100.0%

Operating Margin (2100.7%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(88.3%)

Return on Equity

(26.0%)

Return on Assets

(23.5%)

Liquidity & Leverage

Current Ratio

12.39

Quick Ratio

11.74

Debt / Equity

0.06

Total Cash

117.22M

Total Debt

12.71M

About

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.